LCTX — Lineage Cell Therapeutics Balance Sheet

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual balance sheet for Lineage Cell Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	—	—	—	—	—
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Cash and Equivalents
Short Term Investments
Cash and Short Term Investments	58.4	57.9	35.5	47.8	55.8
Net Total Accounts Receivable
Net Total Receivables	50.8	0.297	0.745	0.638	0.891
Prepaid Expenses
Total Current Assets	112	60	38.4	51	59.2
Gross Property, Plant And Equipment
Accumulated Depreciation
Net Property, Plant And Equipment	4.87	5.67	4.77	4.39	4.7
Net Goodwill
Net Intangible Assets
Other Long Term Assets
Total Assets	175	124	101	113	113
Accounts Payable
Accrued Expenses
Notes Payable / Short Term Debt
Current Portion of Long Term Debt / Capital Leases
Total Other Current Liabilities
Total Current Liabilities	47.1	19	18	14	11.4
Capital Lease Obligations
Total Long Term Debt
Total Debt
Deferred Income Tax
Minority Interest
Total Other Liabilities
Total Liabilities	82.3	50.3	37.6	34.8	68
Non Redeemable Preferred Stock
Common Stock
Retained Earnings (Accumulated Deficit)
Other Equity
Total Equity	92.2	73.3	63.4	78.4	44.5
Total Liabilities & Shareholders' Equity	175	124	101	113	113
Total Common Shares Outstanding